Fortress Biotech, Inc. - 31 Mar 2023 Form 4 Insider Report for AVENUE THERAPEUTICS, INC. (ATXI)

Role
10%+ Owner
Signature
/s/ Samuel Berry, General Counsel and Authorized Agent
Issuer symbol
ATXI
Transactions as of
31 Mar 2023
Net transactions value
$0
Form type
4
Filing time
04 Apr 2023, 16:08:05 UTC
Previous filing
06 Jan 2023
Next filing
03 Jul 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ATXI COMMON STOCK, PAR VALUE $0.0001 Award $0 +52,419 +9.3% $0.000000 613,980 31 Mar 2023 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Issuer is required to grant to the Reporting Person an equity fee in shares of the Issuer's Common Stock equal to 2.5% of the gross amount of any debt or equity financing consummated by the Issuer. These shares were granted by the Issuer to the Reporting Person following the closing of an equity financing.